Trial Profile
A phase II study of bevacizumab, irinotecan and capecitabine in patients with previously untreated metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Feb 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms XELIRI-A
- 06 Oct 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 06 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Feb 2009 Planned end date changed from 1 Jul 2008 to 1 Jul 2009 as reported by ClinicalTrials.gov.